COSCIENS Biopharma (TSE:CSCI) has released an update.
COSCIENS Biopharma Inc. has reported a significant increase in total assets, rising to $50,045 thousand as of June 30, 2024, from $23,745 thousand at the end of the previous year. The financial statements also show a comprehensive loss, with retained earnings dropping to $1,533 thousand and an accumulated other comprehensive loss of $1,218 thousand. These interim results highlight the company’s current financial position and performance over the first half of the year.
For further insights into TSE:CSCI stock, check out TipRanks’ Stock Analysis page.
